Peter Thompson Sells 235,863 Shares of Sionna Therapeutics (NASDAQ:SION) Stock

Key Points

• Director Peter Thompson sold 235,863 shares on April 15 at an average price of $44.64 for about $10.53 million, reducing his stake by 6.77% to 3,247,025 shares; the trade was executed under a pre‑arranged Rule 10b5‑1 plan.
• SION traded at $45.24 (up $0.15) with volume of 817,609 versus an average of 382,339, 50‑day/200‑day SMAs of $37.40/$38.18, and a 12‑month range of $9.39–$46.10.
• Sionna reported Q1 EPS of ($0.46), beating estimates of ($0.61), and analysts hold a consensus Moderate Buy rating with a $50.57 average price target.

Sionna Therapeutics, Inc. (NASDAQ:SION - Get Free Report) Director Peter Thompson sold 235,863 shares of the business's stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $44.64, for a total transaction of $10,528,924.32. Following the sale, the director directly owned 3,247,025 shares in the company, valued at $144,947,196. The trade was a 6.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sionna Therapeutics Trading Up 0.3%

NASDAQ:SION traded up $0.15 during trading hours on Thursday, reaching $45.24. The company had a trading volume of 817,609 shares, compared to its average volume of 382,339. The business's 50-day simple moving average is $37.40 and its two-hundred day simple moving average is $38.18. Sionna Therapeutics, Inc. has a twelve month low of $9.39 and a twelve month high of $46.10.

Sionna Therapeutics (NASDAQ:SION - Get Free Report) last posted its quarterly earnings results on Monday, March 2nd. The company reported ($0.46) EPS for the quarter, topping analysts' consensus estimates of ($0.61) by $0.15.

Wall Street Analyst Weigh In

SION has been the subject of several research reports. BTIG Research restated a "buy" rating and set a $58.00 price target on shares of Sionna Therapeutics in a research report on Monday, March 2nd. Raymond James Financial reissued a "strong-buy" rating and set a $53.00 target price on shares of Sionna Therapeutics in a research report on Monday, January 5th. Weiss Ratings restated a "sell (e+)" rating on shares of Sionna Therapeutics in a research note on Monday, December 29th. UBS Group reaffirmed a "buy" rating on shares of Sionna Therapeutics in a report on Monday, March 2nd. Finally, Citigroup started coverage on shares of Sionna Therapeutics in a report on Tuesday, February 24th. They issued an "outperform" rating on the stock. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Sionna Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $50.57.

Hedge Funds Weigh In On Sionna Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. TD Asset Management Inc boosted its position in Sionna Therapeutics by 74.3% during the third quarter. TD Asset Management Inc now owns 87,082 shares of the company's stock worth $2,561,000 after purchasing an additional 37,116 shares during the period. China Universal Asset Management Co. Ltd. purchased a new stake in Sionna Therapeutics during the 3rd quarter worth about $147,000. Los Angeles Capital Management LLC purchased a new stake in Sionna Therapeutics during the 4th quarter worth about $197,000. Bank of America Corp DE lifted its holdings in Sionna Therapeutics by 8.8% during the 3rd quarter. Bank of America Corp DE now owns 6,541 shares of the company's stock worth $192,000 after purchasing an additional 529 shares in the last quarter. Finally, AlphaCentric Advisors LLC purchased a new stake in Sionna Therapeutics during the 4th quarter worth about $112,000.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.